CAR T-cell therapy is a revolutionary type of immunotherapy approved for some cancers. At Providence Cancer Institute, a new clinical study of CAR T-cell therapy is open to people with clear cell renal cell carcinoma, the most common type of kidney cancer.
Providence is one of the few highly specialized centers in the Pacific Northwest to offer CAR T-cell therapy. View the study details here:
Phase I Study of ALLO-316 and ALLO-647 for Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)
The purpose of the TRAVERSE study is to assess the safety and effectiveness of the investigational treatments ALLO-316 CAR T-cell therapy plus ALLO-647 immunotherapy in people whose kidney cancer has advanced following other treatments or spread throughout the body (metastatic). Study investigators will also determine the safe dose of ALLO-316 following treatment with ALLO-647.
ALLO-316 is a treatment in which T cells, a type of white blood cell, are collected from healthy donors (allogenic). In a laboratory facility, the T cells are modified with a special receptor (CAR: chimeric antigen receptor), primed to detect and bind to a marker (CD70) prevalent on kidney cancer cells, and multiplied. Then the CAR T cells are given intravenously (by vein) to people with kidney cancer. When the CAR T cells bind to the cancer cells, they initiate an immune response to destroy the cancer.
Prior to receiving ALLO-316, study participants will receive a short course of chemotherapy (fludarabine and cyclophosphamide) and ALLO-647, an antibody that binds to a marker (CD52) found on white blood cells. These treatments temporarily suppress the immune system to make room for the CAR T cells and allow them to remain in the body long enough to attack the cancer. All treatments in this study are given intravenously.
To be eligible for this study, participants must meet several criteria, including but not limited to the following:
- Patients 18 years or older with kidney cancer with a predominant clear cell component
- Progression of advanced or metastatic kidney cancer after treatment with immune checkpoint inhibitors and VGEF inhibitors
- No previous treatments with anti-CD70 or anti-CD52 therapies
For more information or to refer patients to this study, please call our Clinical Research office at 503-215-2614 or submit a referral form.
More kidney cancer studies
Providence Cancer Institute offers clinical studies for people with cancers of the genitourinary tract, including kidney, prostate and bladder cancers. See all studies for genitourinary cancers and studies for multiple cancers.
New research studies are added frequently. Please visit our website to view our all cancer clinical studies.
Leaders in immunotherapy for kidney cancer
The TRAVERSE study is led by Brendan Curti, M.D., medical director of Genitourinary Oncology Research at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute.
One of the first applications of immunotherapy in cancer medicine was the use of high-dose interleukin-2 (IL-2) in patients with kidney cancer. Under Dr. Curti’s leadership, Providence is home to the largest IL-2 program in Oregon for patients with metastatic kidney cancer, and is among the top five nationwide.
Dr. Curti contributed to the clinical development of targeted therapies and immunotherapies for genitourinary cancers, and is an active investigator of other treatments for kidney cancer.
To learn more, visit the Providence Immunotherapy Program.